Blue Matter

Strategic consulting firm serving the life sciences industry, with operations across the US & Europe; Specialized expertise in oncology, CNS, & rare diseases

[Blue Matter @BlueMatter1]

Medical comms that get deployed to the field often become detached from the core strategy that initiated them. For #MedicalAffairs, that's a problem. Here's what to do about it >> https://t.co/IaCqOoTft1

[Blue Matter @BlueMatter1]

On May 13, Blue Matter hosted a roundtable discussion with 27 senior biopharma leaders in the Boston area. Now, you can read a summary of these open and insightful conversations: https://t.co/NLjCtS0Yrk

#biotech #pharmaceuticals #biopharma #BlueMatter

[Blue Matter @BlueMatter1]

Our team recently attended the ISPOR 2026 meeting in Philadelphia. Here are 5 key themes they saw at the conference >> https://t.co/mgBBJxoRqv

#HEOR #RWE #HealthEconomics #biotech #pharmaceuticals

[Blue Matter @BlueMatter1]

How can you drive access & reimbursement success for a cell / gene therapy? This new article explains why CGT reimbursement is different from specialty pharma, & offers some key success factors for manufacturers. >> https://t.co/m05ZDy2BAr

#biotech #pharmaceuticals #celltherapy

[Blue Matter @BlueMatter1]

Part 3 in our ongoing series on cell / gene therapies >> https://t.co/sPXiD4BpoT

[Blue Matter @BlueMatter1]

NEW REPORT - Key Success Factors for a Best Practice Key Account Management Organization >> https://t.co/lApMKL8rBt

#pharmaceutical #biotech #KeyAccountManagement #biopharma #marketaccess

[Blue Matter @BlueMatter1]

NEW REPORT - Key Success Factors for Building a Best Practice #PatientServices Organization >> https://t.co/FYNspiFBk7

#pharmaceutical #biotech #marketaccess #patientcentricity

[Blue Matter @BlueMatter1]

Key Success Factors for Building a "Best Practice" US #MarketAccess Organization >> https://t.co/Wai4nBb9eI
#biotech #pharmaceuticals #organizationalexcellence

[Blue Matter @BlueMatter1]

Blue Matter analysis of #biopharma deal activity during 2H2025 & what it means for 2026 & beyond >> https://t.co/ENo7dfHUiP

[Blue Matter @BlueMatter1]

Recently, our team attended the MAPS Americas meeting in Denver. Here are 5 key themes from the discussions there >> https://t.co/DJG8nNbwRe

#medicalaffairs #biotech #pharmaceutical

[Blue Matter @BlueMatter1]

Often, revolutionary technologies make things worse before they make them better. Is that what #AI is doing in #biopharma R&D? >> https://t.co/8vPaQWVeSH

#artificialintelligence #pharmaceuticals

[Blue Matter @BlueMatter1]

4 key takeaways from the recent Informa #RareDisease Summit in Philadelphia >> https://t.co/wB1kHVZizc

[Blue Matter @BlueMatter1]

What was once a relatively stable “buy-and-bill” ecosystem for physician-administered drugs is being significantly reshaped by a range of market and policy factors. Read our latest paper to learn more about them.

https://t.co/WiNfXzJxZj

[Blue Matter @BlueMatter1]

NEW: 5 key dynamics shaping the market for buy and bill drugs >> https://t.co/J4TnRxIoXx

[Blue Matter @BlueMatter1]

A look at the global #CDMO market & the opportunities, risks, & investment playbook for private equity >> https://t.co/enxnWOwMfw

[Blue Matter @BlueMatter1]

10 Critical Success Factors for Launching & Commercializing Cell & Gene Therapies >> https://t.co/aarSqrv4qq

#pharmaceutical #biotech #celltherapies #genetherapies #celltherapy #genetherapy

[Blue Matter @BlueMatter1]

4 trends that will drive change in #RareDisease therapies in 2026 & beyond >> https://t.co/0ytdHmR3Es

#RareDiseases #biotech #pharmaceuticals #biopharma

[Blue Matter @BlueMatter1]

NEW >> 10 critical success factors for launching & commercializing cell / gene therapies >> https://t.co/WZeUc5tnvq

[Blue Matter @BlueMatter1]

#CNS market outlook for 2026 & beyond (biopharma R&D, commercialization) >> https://t.co/C2NLEQIE9u

[Blue Matter @BlueMatter1]

A look at opportunities, risks, and PE investment strategies in the global #CDMO market >> https://t.co/ZfAyISJmoS